|Investigation||:||Carcinoembyronic Antigen (CEA)|
|Spec container||:||Serum Gel|
|Volume required||:||5 ml|
|Reference range||:||≤4.7 µg/l|
Please note: From 11rd November 2013 , a new method of CEA analysis was introduced which will decrease results by upto 25%.
Carcinoembryonic antigen (CEA)
Reference range: <5µg/l
Carcinoembryonic antigen (CEA) is a tumour-associated, oncofetal antigen observed in embryonic and foetal tissues. The CEA family is a heterogeneous group of cell-surface glycoproteins.
Malignancies with elevated CEA:
CEA is raised in 60% patients with colorectal carcinoma, more commonly in those with advanced disease ( raised in 80-100% of those with hepatic metastases). CEA may be elevated in almost any advanced adenocarcinoma eg lung, breast, pancreas, liver, stomach, ovary, prostrate and in medullary carcinoma of thyroid.
Benign diseases which may have elevated CEA:
Lesser elevations occur in a number of non-malignant conditions eg hepatitis, cirrhosis, alcoholic liver disease, obstructive jaundice, pancreatic disease, inflammatory bowel disease, renal impairment, benign breast disease, collagen vascular disease, following treatment with 5-Fluorouracil and in some heavy smokers.
CEA is neither sufficiently specific nor sensitive enough to be used in screening for early colorectal carcinoma in asymptomatic individuals.
Main clinical applications:
New CEA reference interval 01/05/21, results unaffected.
AUH service users: new CEA units ug/L are equivalent to previous (ng/mL).
Laboratory Services Home Page